Drug class
Fumarate prodrug; disease-modifying therapy for multiple sclerosis
Mechanism of action
Rapidly hydrolysed to monomethyl fumarate (MMF), the same active metabolite formed from dimethyl fumarate. The mechanism of MMF in multiple sclerosis is not fully understood; Nrf2 pathway activation and modulation of inflammatory and oxidative-stress responses are proposed.
General use cases
- Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
